Xiamen Amoytop Biotech Co., Ltd.
32
3
3
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 32 trials
100.0%
+13.5% vs industry average
28%
9 trials in Phase 3/4
5%
1 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (32)
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Role: lead
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
Role: lead
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
Role: lead
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
Role: lead
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
Role: lead
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
Role: lead
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..
Role: lead
Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia
Role: collaborator
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
Role: lead
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
Role: lead
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Role: lead
A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Role: lead
A Trial of YPEG-rhGH in Children With Short Stature
Role: lead
Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children
Role: lead
A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
Role: lead
Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy
Role: collaborator
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
Role: lead
Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy
Role: lead
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Role: lead
A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B
Role: lead